Nicotinamide in type I diabetes: Mechanism of action revisited

Diabetes Care

Volumn 22, Issue SUPPL. 2, 1999, Pages

  Kolb, Hubert ^a,b   Burkart, Volker ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

APOPTOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NONHUMAN; RADIOSENSITIZATION; STREPTOZOCIN DIABETES; ANIMAL; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS ISLET; REVIEW;

ADP RIBOSE TRANSFERASES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; NIACINAMIDE; POLY(ADP-RIBOSE) POLYMERASES;

EID: 0033011536     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (60)

1. Elliott RB, Pilcher CC, Ferguson DM, Stewart AW: A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metabol 9:501-509, 1996
2. Lampeter EF: Intervention with nicotinamide in pre-type 1 diabetes: the Deutsche Nicotinamid Interventionsstudie - DENIS. Diabete Metab 19:105-109, 1993
3. Gale EAM, Bingley PJ: Can we prevent IDDM? Diabetes Care 17:339-344, 1994
4. Elliott RB, Chase HP: Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34:362-365, 1991
5. Herskowitz RD, Jackson RA, Soeldner JS, Eisenbarth GS: Pilot trial to prevent type 1 diabetes: progression to overt IDDM despite oral nicotinamide. J Autoimmun 2:733-737, 1989
6. Manna R, Migliore A, Martin LS, Ferrara E, Ponte E, Marietti G, Scuderi F, Cristiano G, Ghirlanda G, Gambassi G: Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Br J Clin Pract 46:177-179, 1992
7. Lazarow A: Protection against alloxan diabetes. Anat Rec 97:353, 1947
8. Lazarow A, Liambies L, Tausch AJ: Protection against diabetes with nicotinamide. J Lab Clin Med 36:249-258, 1950
9. Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui S: Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. Diabetes 31:749-753, 1982
10. Elliott RB, Pilcher CC, Stewart A, Ferguson D, McGregor MA: The use of nicotinamide in the prevention of type 1 diabetes Ann NY Acad Sci U S A 696:333-343, 1993
11. Yamamoto K, Miyagawa J, Itoh K, Nakajima H, Waguri M, Shimada T, Yasuda K, Kono N, Namba M, Kuwajima M, Hanafusa T, Matsuzawa Y: Differentiation of β-cells from ductal cells and acceleration of this process by nicotinamide: ultrastructural study on the non-obese diabetic (NOD) mouse with overt diabetes. Biomed Res Tokyo 18:171-178, 1997
12. Kolb H, Schmidt M, Kiesel U: Immunomodulatory drugs in type 1 diabetes. In Immunotherapy of Type 1 Diabetes and Selected Autoimmune Disorders. Eisenbarth GS, Ed. Boca Raton, FL, CRC Press, 1989, p. 111-122
13. Sarri Y, Mendola J, Ferrer J, Gomis R: Preventive effects of nicotinamide administration on spontaneous diabetes of BB rats. Med Sci Res 17:987-988, 1989
14. Hermitte L, Vialettes B, Atlef N, Payan MJ, Doll N, Scheimann A, Vague P: High dose nicotinamide fails to prevent diabetes in BB rats. Autoimmunity 5:79-86, 1989
15. Pan JQ, Chan EK, Cheta D, Schranz V, Charles MA: The effect of nicotinamide and glimepiride on diabetes prevention in BB rats life Sci 57:1525-1532, 1995
16. Pozzilli P, Browne PD, Kolb H: Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM: the nicotinamide trialists. Diabetes Care 19:1357-1363, 1996
17. Andersen HU, Jorgensen KH, Egeberg J, Mandrup-Poulsen T, Nerup J: Nicotinamide prevents interleukin-1 effects on accumulated insulin release and nitric oxide production in rat islets of Langerhans. Diabetes 43:770-777, 1994
18. Burkart V, Gross-Eick A, Bellmann K, Radons J, Kolb H: Suppression of nitric oxide toxicity in islet cells by alpha-tocopherol. FEBS Lett 364:259-263, 1995
19. Rankin PW, Jacobson EL, Benjamin RC, Moss J, Jacobson MK: Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem 264:4312-4317, 1989
20. Banasik M, Komura H, Shimoyama M, Ueda K: Specific inhibitors of poly(ADP-ribose)synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267:1569-1575, 1992
21. Pellatdeceunynck C, Wietzerbin J, Drapier JC: Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages. Biochem J 297:53-58, 1994
22. Hauschildt S, Scheipers P, Bessler WG: Inhibitors of poly(ADP-ribose)polymerase suppress lipopolysaccharide-induced nitrite formation in macrophages. Biochem Biophys Res Commun 179:865-871, 1991
23. Petley A, Macklin B, Renwick AG, Wilkin TJ: The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 44:152-155, 1995
24. Stratford MRL, Rojas A, Hall DW, Dennis MF, Dische S, Joiner MC, Hodgkiss RJ: Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother Oncol 25:37-42, 1992
25. Satoh MS, Lindahl T: Role of poly(ADP-ribose)formation in DNA repair. Nature 356:356-358, 1992
26. DeMurcia G, Schreiber V, Molinete M, Saulier B, Poch O, Massen M, Niedergang C, Menissier DeMurcia J: Structure and function of poly(ADP-ribose)polymerase. Mol Cell Biochem 138:15-24, 1994
27. Rakieten N, Rakieten ML, Nadkarni MV: Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 29:91-98, 1963
28. Like AA, Rossini AA: Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193:415-417, 1976
29. Rasschaert J, Eizirik DL, Malaisse WJ: Long term in vitro effects of streptozotocin, interleukin-1, and high glucose concentration on the activity of mitochondrial dehydrogenases and the secretion of insulin in pancreatic islets. Endocrinol 130:3522-3528, 1992
30. Kolb H, Kröncke K-D: Lessons from the low dose streptozocin model in mice. Diabetes Rev 1:116-126, 1993
31. Kröncke K-D, Fehsel K, Sommer A, Rodriguez M-L, Kolb-Bachofen V: Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotocin contributes to islet cell DNA damage. Biol Chem Hoppe-Seyler 376:179-185, 1995
32. Turk J, Corbett JA, Ramanadham S, Bohrer A, McDaniel L: Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem Biophys Res Commun 197:1458-1464, 1993
33. Wang Z-Q, Auer B, Stingl L, Berghammer H, Haidacher D, Schwaiger M, Wagner EF: Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 9:509-520, 1995
34. Stratford MR, Dennis MF, Hoskin P, Phillips H, Hodgkiss RJ, Rojas A: Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring. Br J Cancer 74:16-21, 1996
35. Horsman MR, Hoyer M, Honess DJ, Dennis IF, Overgaard J: Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol 27:131-139, 1993
36. Riklis E, Kol R, Marko R: Trends and developments in radioprotection: the effect of nicotinamide on DNA repair. Int J Radiat Biol 57:699-708, 1990
37. Chen G, Zeller WJ: Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensitive and DDP-resistant rat ovarian tumor cell lines. Cancer Lett 67:27-33, 1992
38. Olsson AR, Sheng Y, Pero RW, Chaplin DJ, Horsman MR: DNA damage and repair in tumour and non-tumour tissues of mice induced by nicotinamide. Br J Cancer 74:368-373, 1996
39. Horsman MR: Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumors: a review. Acta Oncologica 34:571-587, 1995
40. Thomas CD, Prade M, Guichard M: Tumour oxygenation, radiosensitivity, and necrosis before and/or after nicotinamide, carbogen and perflubron emulsion administration. Int J Rad Biol 67:597-605, 1995
41. Price MJ, Li LT, Tward JD, Bublik I, McBride WH, Lavey RS: Effect of nicotinamide and pentoxifylline on normal tissue and FSa tumor oxygenation. Acta Oncologica 34:391-395, 1995
42. Hirst DG, Kennovin GD, Tozer GM, Prise VE, Flitney EW: The modification of blood flow in tumours and their supplying arteries by nicotinamide. Acta Oncologica 34:397-400, 1995
43. Peters CE, Chaplin DJ, Hirst DG: Nicotinamide reduces tumour interstitial fluid pressure in a dose-dependent manner. Br J Radiol 70:160-167, 1997
44. Hiromatsu Y, Sato M, Yamada K, Nonaka K: Inhibitory effects of nicotinamide on recombinant human interferon-gamma-induced intercellular adhesion molecule-1 (ICAM-1) and HLA-DR antigen expression on cultured human endothelial cells. Immunology Lett 31:35-40, 1991
45. Berk MA, Lorinez AL: The treatment of bullous pemphigoid with tetracycline and niacinamide. Arch Dermatol 122:670-674, 1986
46. Miesel M, Kurpisz M, Kröger H: Modulation of inflammatory arthritis by inhibition of poly(ADP-ribose)polymerase. Inflammation 19:379-387, 1995
47. Greenbaum CJ, Kahn SE, Palmer JP: Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes 45:1631-1634, 1996
48. Paul TL, Hramiak IM, Mahon JL, Freeman D, Atkinson P, Finegood DT, Dupre J: Nicotinamide and insulin sensitivity (Letter). Diabetologia 36:369, 1993
49. Bingley PJ, Caldas G, Bonfanti R, Gale EA: Nicotinamide and insulin secretion in normal subjects. Diabetologia 36:675-677, 1993
50. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H, the DENIS Group: The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. Diabetes 47:980-984, 1998
51. Nomura I, Kurashige T, Taniguchi T: Inhibitory effect of interferon-gamma-dependent induction of major histocompatibility complex class II antigen by expressing exogenous poly(ADP-ribose)synthetase gene. Biochem Biophys Res Commun 175:685-689, 1991
52. Tomoda T, Kurashige K, Taniguchi T: Inhibition of interferon-gamma-induced and phorbol ester-induced HLA-DR and interleukin-1 production by the expression of a transfected poly(ADP-ribose)synthetase gene in human leukemia THP-1 cells. Biochim Biophys Acta 1135:79-83, 1992
53. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Libelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-T, Yu YL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37-43, 1995
54. Dimmeler S, Haendeler J, Nehls M, Zeiher AM: Suppression of apoptosis by nitric oxide via induction of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J. Exp Med 185:601-607, 1997
55. Hoshino J, Koeppel C, Westhauer E: 3-aminobenzamide enhances dexamethasone-mediated mouse thymocyte depletion in vivo: implication for a role of poly ADP-ribosylation in the negative selection of immature thymocytes. Biochim Biophys Acta 1201:516-522, 1994
56. Lund F, Solvason N, Grimaldi JC, Parkhouse RME, Howard M: Murine CD38: an immunoregulatory ectoenzyme. Immunol Today 16:469-473, 1995
57. Wang J, Nemoto E, Dennert G: Regulation of cytotoxic T cell functions by GPI-anchored ecto-ADP-ribosyltransferase. Adv Exp Med Biol 419:191-201, 1997
58. Yasue T, Nishizumi N, Aizawa S, Yamamoto T, Miyake K, Mizoguchi C, Uehara S, Kikuchi Y, Takatsu K: A critical role of lyn and fyn for B cell responses to CD38 ligation to interleukin 5. Proc Natl Acad Sci U S A 94:10307-10312, 1997
59. Kolb H: Benign versus destructive insulitis. Diabetes Metab Rev 13:139-146, 1997
60. Waite DJ, Appel MC, Handler ES, Mordes JP, Rossini AA, Greiner DL: Ontogeny and immunohistochemical localization of thymus-dependent and thymus-independent RT6+ cells in the rat. Am J Pathol 148:2043-2056, 1996